Press Releases

GlobeNewswire, Inc.

Alignment with FDA on CMC and device plans for Phase 3 Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials Further strengthening of US and EU mebufotenin patent estate Phase 2a results in postpartum depression published in The...

GlobeNewswire, Inc.

OPGx-BEST1 Cohort 1 Topline Data Expected in Second Week of September 2026 Enrollment Completed in LCA5 Registrational Trial with Dosing Planned for Q4 2026 RDH12, MERTK and RHO Programs Advancing with Upcoming Initiation of Clinical Testing Cash...

GlobeNewswire, Inc.

CHICAGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- New TransUnion (NYSE: TRU) research finds that consumer credit remains widely available despite economic uncertainty, while credit usage continues to grow at a pace largely consistent with inflation....

GlobeNewswire, Inc.

Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., Aug. 06, 2026...

GlobeNewswire, Inc.

Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026; topline data from Phase 3 study in non-infectious uveitis (NIU) expected in the second half of calendar...

GlobeNewswire, Inc.

AUSTIN, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Commerce.com, Inc. (Nasdaq: CMRC), a data-centric provider of an open, AI-driven commerce ecosystem that enables businesses to unlock data, power intelligent discovery and deliver personalized...

GlobeNewswire, Inc.

- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Timelines Reaffirmed for Upcoming Top Line Results from Phase 1b Proof-of-Concept (POC)...

GlobeNewswire, Inc.

Generated second quarter 2026 XDEMVY® net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million Pending acquisition of Alkeus Pharmaceuticals to...

GlobeNewswire, Inc.

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 Phase 2 TRITON trial of Descartes-08 in myositis on track with data from...

GlobeNewswire, Inc.

CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2026 Budoprutug clinical programs continue to advance, with data...

GlobeNewswire, Inc.

Second quarter revenue grew 36% year-over-year to $1.12 billion Robust growth of larger customers, with about 4,720 $100k+ ARR customers, up from about 3,850 a year ago Launched AI-powered Bits Code, Bits Chat, and Bits Agent Builder for general...

GlobeNewswire, Inc.

Worldwide revenue of $388.2 million in the second quarter of 2026 GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 Adjusted fully diluted earnings per share of $1.55, compared to $1.57 in the second...

GlobeNewswire, Inc.

SHANGHAI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Atour Lifestyle Holdings Limited (“Atour” or the “Company”) (NASDAQ: ATAT), a leading lifestyle group in China, today announced that it will report its unaudited financial results for the second quarter...

GlobeNewswire, Inc.

Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with...

GlobeNewswire, Inc.

- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potential to treat multiple myeloma and other hematological...

GlobeNewswire, Inc.

Vancouver, British Columbia, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X450) ("Deep Sea Minerals" or the "Company"), a seabed mineral exploration and development company focused on advancing...

GlobeNewswire, Inc.

Vancouver, British Columbia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Rocker Doctor AI Inc. (the “Company” or “Rocket Doctor AI”) (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) is pleased to announce, further to its news release of July 28, 2026, that it has...

GlobeNewswire, Inc.

Revenue of $731.1 million and Direct-to-Consumer (“DTC”) Revenue of $286.9 million Revenue Decreased (1.8)% Sequentially and Increased 5.0% Year Over Year DTC Platforms Revenue Decreased (1.7)% Sequentially and Increased 63.1% Year Over Year...

GlobeNewswire, Inc.

BOSTON HEIGHTS, Ohio, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Arhaus, Inc. (“Arhaus” or the “Company”) (NASDAQ: ARHS), a premium home furnishing brand known for responsibly sourced, artisan-crafted products and heirloom-quality design, reported second...

GlobeNewswire, Inc.

Results for the Quarter Ended June 30, 2026, and Other Recent Highlights: Net investment income per share for the quarter was $0.40, compared to $0.38 for the quarter ended March 31, 2026 Net asset value (“NAV”) per share as of the end of the...